The following four neurological products are likely to reach market next year. Carving out sales will be an entirely different problem. 

A swathe of generic lurasidone launches following the originator’s US patent expiry may trigger a shift in the antipsychotics space.

Sublingual film product Igalmi is approved to treat agitation related to schizophrenia and bipolar disorder, but BioXcel also is targeting a bigger market opportunity in Alzheimer’s dementia.

The highly genericized bipolar disorder market is set for change as both new long-acting injectable formulations of older products and novel therapies reach the market, while firms like NRx and BioXcel target major unmet needs in a disease that needs more R&D.